Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Department of Medicine, Reading Hospital, Tower Health System, West Reading, PA, USA.
AIDS Res Ther. 2021 Nov 16;18(1):85. doi: 10.1186/s12981-021-00395-3.
Programmes that merge management of Human Immunodeficiency Virus (HIV) and tuberculosis (TB) aim to improve HIV/TB co-infected patients' access to comprehensive treatment. However, several reports from sub-Saharan Africa (SSA) indicate suboptimal uptake of antiretroviral therapy (ART) even after integration of HIV and TB treatment. This study assessed ART uptake, its barriers and enablers in programmes integrating TB and HIV treatment in SSA.
A systematic review was performed. Seven databases were searched for eligible quantitative, qualitative and mixed-methods studies published from March 2004 through July 2019. Random-effects meta-analysis was used to obtain pooled estimates of ART uptake. A thematic approach was used to analyse and synthesise data on barriers and enablers.
Of 5139 references identified, 27 were included in the review: 23/27 estimated ART uptake and 10/27 assessed barriers to and/or enablers of ART uptake. The pooled ART uptake was 53% (95% CI: 42, 63%) and between-study heterogeneity was high (I = 99.71%, p < 0.001). WHO guideline on collaborative TB/HIV activities and sample size were associated with heterogeneity. There were statistically significant subgroup effects with high heterogeneity after subgroup analyses by region, guideline on collaborative TB/HIV activities, study design, and sample size. The most frequently described socioeconomic and individual level barriers to ART uptake were stigma, low income, and younger age group. The most frequently reported health system-related barriers were limited staff capacity, shortages in medical supplies, lack of infrastructure, and poor adherence to or lack of treatment guidelines. Clinical barriers included intolerance to anti-TB drugs, fear of drug toxicity, and contraindications to antiretrovirals. Health system enablers included good management of the procurement, supply, and dispensation chain; convenience and accessibility of treatment services; and strong staff capacity. Availability of psychosocial support was the most frequently reported enabler of uptake at the community level.
In SSA, programmes integrating treatment of TB and HIV do not, in general, achieve high ART uptake but we observe a net improvement in uptake after WHO issued the 2012 guidelines on collaborative TB/HIV activities. The recurrence of specific modifiable system-level and patient-level factors in the literature reveals key intervention points to improve ART uptake in these programmes. Systematic review registration: CRD42019131933.
将人类免疫缺陷病毒 (HIV) 和结核病 (TB) 管理相结合的项目旨在提高 HIV/TB 合并感染患者获得全面治疗的机会。然而,来自撒哈拉以南非洲 (SSA) 的几份报告表明,即使在整合 HIV 和结核病治疗后,接受抗逆转录病毒治疗 (ART) 的人数仍然不理想。本研究评估了 SSA 中整合结核病和 HIV 治疗的项目中 ART 的采用情况、障碍和促进因素。
进行了系统评价。从 2004 年 3 月至 2019 年 7 月,在七个数据库中搜索了符合条件的定量、定性和混合方法研究。使用随机效应荟萃分析获得 ART 采用的汇总估计值。采用主题方法分析和综合 ART 采用的障碍和促进因素的数据。
在 5139 条参考文献中,有 27 条被纳入综述:23/27 条评估了 ART 的采用情况,10/27 条评估了 ART 采用的障碍和/或促进因素。ART 采用率为 53%(95%CI:42,63%),研究间异质性很高(I=99.71%,p<0.001)。世界卫生组织 (WHO) 关于合作性结核病/艾滋病毒活动的指导方针和样本量与异质性有关。按地区、合作性结核病/艾滋病毒活动指导方针、研究设计和样本量进行亚组分析后,存在统计学显著的亚组效应和高度异质性。最常描述的社会经济和个人层面 ART 采用障碍是污名化、低收入和年龄较小的群体。最常报告的卫生系统相关障碍包括工作人员能力有限、医疗用品短缺、基础设施不足以及不遵守或缺乏治疗指南。临床障碍包括对抗结核药物不耐受、对药物毒性的恐惧以及对抗逆转录病毒药物的禁忌症。卫生系统促进因素包括良好管理采购、供应和分发链;治疗服务的便利性和可及性;以及强大的员工能力。社区层面最常报告的促进因素是提供心理社会支持。
在 SSA,总体而言,整合结核病和 HIV 治疗的项目并未实现高 ART 采用率,但我们观察到在世界卫生组织发布关于合作性结核病/艾滋病毒活动的 2012 年指导方针后,采用率有所提高。文献中反复出现特定的可修改的系统层面和患者层面因素,这揭示了改善这些项目中 ART 采用率的关键干预点。系统评价登记号:CRD42019131933。